GSK (GSK) Stock Analysis

November 11, 2026

This is a peer-relative look at GSK (GSK): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

GSK (GSK) trades as an ADR rather than ordinary local shares — read it with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile fields for GSK (GSK)
Profile Item	GSK
Name	GSK plc ADR
Country/Region	United Kingdom
GICS Sector	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals
GICS Sub-Industry	Pharmaceuticals
Market Capitalization	100.88 billion USD
Currency	USD
Exchange	NYSE
Listing Date	March 28, 1980
Security Type	ADR

Price Performance

Cumulative Growth

GSK

GSPC

GSK (GSK) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for GSK (GSK) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for GSK (GSK) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

GSK (GSK) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: GSK	Industry group median
Total Return (1Y)	13.73%	24.62%
Total Return (3Y, Annualized)	18.65%	20.37%
Total Return (5Y, Annualized)	7.97%	-4.02%

Risk Profile

Drawdown History

GSK

GSPC

GSK (GSK) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for GSK (GSK) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

GSK (GSK) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: GSK	Industry group median
Volatility (1Y, Annualized)	26.25%	66.36%
Beta (5Y)	0.31	0.93
Max Drawdown (5Y)	-37.63%	-80.19%

Risk-Adjusted Performance

Risk-Return Positioning

Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. GSK is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

GSK (GSK) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: GSK	Industry group median
Sharpe Ratio (1Y)	0.36	0.36
Sortino Ratio (1Y)	0.56	0.58

Profitability

ROE (TTM)

GSK (GSK) posts ROE of 28.27%, in the upper peer quartile. That suggests the company earns more from each dollar of shareholders’ equity than most industry peers, a useful capital-efficiency signal.

GSK

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.27%

Group distribution

Max: 109.18%
GSK: 28.27%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Largest peers

LLY: 86.02%
GSK: 28.27%
NVS: 24.33%
AZN: 22.57%
JNJ: 20.02%
MRK: 5.06%
ABBV: --

Where GSK (GSK) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

GSK (GSK) keeps 12.97% of revenue as net profit, putting net margin in the upper peer quartile. After operating costs, interest, and taxes, more of each sales dollar reaches shareholders than it does at most industry peers.

GSK

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.97%

Group distribution

Max: 18.05%
GSK: 12.97%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Largest peers

LLY: 31.90%
AZN: 17.68%
NVS: 17.49%
JNJ: 16.20%
ABBV: 15.67%
GSK: 12.97%
MRK: 3.64%

Where GSK (GSK) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

GSK (GSK) turns 32.14% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

GSK

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.14%

Group distribution

Max: 83.12%
GSK: 32.14%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Largest peers

LLY: 53.66%
ABBV: 39.59%
MRK: 35.22%
NVS: 34.27%
GSK: 32.14%
AZN: 29.57%
JNJ: 25.74%

Where GSK (GSK) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

GSK (GSK) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: GSK	Industry group median
ROE (TTM)	28.27%	-26.66%
ROA (TTM)	9.24%	-12.50%
Net Margin (TTM)	12.97%	0.00%
Operating Margin (TTM)	32.14%	0.00%
Gross Margin (TTM)	73.79%	37.87%

Growth

Revenue Growth

GSK (GSK) grew revenue 4.11%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.

GSK (GSK): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

GSK (GSK) grew earnings per share 123.15%, in the upper peer quartile. Per-share profits are compounding faster than at most industry peers.

GSK (GSK): EPS Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

Growth Metrics

GSK (GSK) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: GSK	Industry group median
Revenue Growth (YoY)	4.11%	11.45%
Revenue Growth (3Y CAGR)	3.66%	9.94%
EPS Growth (YoY)	123.15%	4.28%
EPS Growth (3Y CAGR)	-27.63%	4.17%

Financial Strength

Current Ratio (MRQ)

GSK (GSK) has current ratio of 0.86, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.

GSK

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.86

Group distribution

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
GSK: 0.86
Min: 0.10

Largest peers

LLY: 1.39
MRK: 1.35
JNJ: 1.02
AZN: 1.01
NVS: 0.88
ABBV: 0.87
GSK: 0.86

Where GSK (GSK) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

GSK (GSK) has debt-to-equity ratio of 1.30, in the higher-leverage quartile for its industry. The heavier reliance on borrowing can make earnings, rates, or refinancing conditions matter more.

GSK

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.30

Group distribution

Max: 1.42
GSK: 1.30
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Largest peers

GSK: 1.30
NVS: 1.29
LLY: 1.23
MRK: 1.20
AZN: 0.66
JNJ: 0.55
ABBV: --

Where GSK (GSK) stands on debt-to-equity ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Financial Strength Metrics

GSK (GSK) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: GSK	Industry group median
Current Ratio (MRQ)	0.86	5.52
Debt / Equity (MRQ)	1.30	0.15
Net Debt / EBITDA	1.88	1.08

Dividends

Dividend Yield (TTM)

GSK (GSK) has dividend yield of 1.57%, above the entire industry range. That headline income is large, but yields this far above peers often come from a falling share price or an at-risk payout, so dividend safety matters more than the percentage itself.

GSK

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.57%

Group distribution

GSK: 1.57%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

NVS: 2.88%
ABBV: 2.40%
MRK: 2.29%
JNJ: 1.94%
AZN: 1.73%
GSK: 1.57%
LLY: 0.49%

Where GSK (GSK) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

GSK (GSK) has payout ratio of 63.33%, above the peer distribution for its industry. The dividend consumes more reported earnings than peers normally do, leaving unusually thin earnings cover.

GSK

Pharmaceuticals, Biotechnology & Life Sciences industry group

63.33%

Group distribution

GSK: 63.33%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

MRK: 343.43%
ABBV: 117.35%
NVS: 90.46%
JNJ: 80.12%
GSK: 63.33%
AZN: 45.38%
LLY: 21.71%

Where GSK (GSK) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

GSK (GSK) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: GSK	Industry group median
Dividend Yield (TTM)	1.57%	0.00%
Dividend Payout Ratio (TTM)	63.33%	0.00%

Valuation

P/E Ratio (TTM)

GSK (GSK) trades at P/E ratio of 17.54, near the industry’s usual earnings multiple. The stock is not showing a clear peer discount or premium on trailing earnings.

GSK

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.54

Group distribution

Max: 85.34
Q3: 43.46
Median: 26.69
GSK: 17.54
Q1: 13.30
Min: 0.07

Largest peers

MRK: 148.21
ABBV: 50.05
LLY: 43.95
JNJ: 41.92
NVS: 31.02
AZN: 26.37
GSK: 17.54

Where GSK (GSK) stands on P/E ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/S Ratio (TTM)

GSK (GSK) trades at 3.01 on P/S ratio, in the lower sales-valuation quartile for its industry. That points to a cheaper revenue stream than most peers, with margin quality still doing the heavy lifting.

GSK

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.01

Group distribution

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
GSK: 3.01
Min: 0.01

Largest peers

LLY: 13.95
ABBV: 7.80
JNJ: 6.69
MRK: 5.37
NVS: 5.35
AZN: 4.63
GSK: 3.01

Where GSK (GSK) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

GSK (GSK) trades at 4.02 on P/B ratio, roughly in line with the industry’s normal price-to-book range. Its balance sheet is not being priced at a clear discount or premium versus peers.

GSK

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.02

Group distribution

Max: 13.53
Q3: 6.54
GSK: 4.02
Median: 3.25
Q1: 1.69
Min: -5.59

Largest peers

LLY: 29.96
NVS: 8.25
JNJ: 8.16
MRK: 8.06
AZN: 5.59
GSK: 4.02
ABBV: -112.34

Where GSK (GSK) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

GSK (GSK) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: GSK	Industry group median
P/E Ratio (TTM)	17.54	26.69
P/S Ratio (TTM)	3.01	7.30
P/B Ratio (MRQ)	4.02	3.25
Free Cash Flow Yield (TTM)	5.28%	-1.66%